Last reviewed · How we verify
Ketorolac Nasal Spray
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic and anti-inflammatory effects.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic and anti-inflammatory effects. Used for Moderate acute pain in adults (nasal spray formulation).
At a glance
| Generic name | Ketorolac Nasal Spray |
|---|---|
| Also known as | SPRIX |
| Sponsor | Hersh, Elliot V., DMD, MS, PhD |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ketorolac blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate pain, inflammation, and fever. When administered as a nasal spray, it delivers the drug directly to nasal tissues for localized anti-inflammatory and analgesic action. This formulation allows for rapid onset of pain relief with potentially lower systemic exposure compared to oral or parenteral routes.
Approved indications
- Moderate acute pain in adults (nasal spray formulation)
Common side effects
- Nasal irritation or discomfort
- Headache
- Rhinitis
- Gastrointestinal upset
- Dizziness
Key clinical trials
- Intranasal Ketorolac Trial (PHASE2)
- Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (PHASE4)
- Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device (PHASE1)
- Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac Nasal Spray CI brief — competitive landscape report
- Ketorolac Nasal Spray updates RSS · CI watch RSS
- Hersh, Elliot V., DMD, MS, PhD portfolio CI